
Isomorphic Labs, an AI company focused on discovering and developing new medicines, has raised €4.5 billion ($5 billion) in a Series C funding round. The company will use the new investment to speed up scientific research and improve its AI technology for drug discovery.
The funding round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz. Alphabet also made a significant investment in the round. Existing investors, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund, also took part.
“When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI,” says Sir Demis Hassabis, founder and CEO of Isomorphic Labs. “Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”
“Isomorphic Labs is building foundational technology for the future of medicine,” adds Konstantine Buhler, Partner at Sequoia Capital. “It’s inspiring to see the Isomorphic team translate advanced AI into a growing portfolio of drug candidates. Using AI to improve human health is one of the most important challenges of our generation. We’re proud to co-lead this round and help further scientific discovery in medicine.”
Founded in 2021, Isomorphic Labs has developed an advanced AI platform to help design new medicines. Its technology uses powerful AI models that can work across different disease areas and types of drugs.
The company is now expanding its AI drug design platform, called IsoDDE, and developing a pipeline of potential new medicines. Its goal is to use AI to make the drug discovery process faster and develop better treatments.
IsoDDE brings together several AI models that can simulate and study how different drugs may work. The platform is designed to support research across multiple medical fields and different types of medicines.
“Every week we are making repeatable scientific advancements enabled by our models,” says Max Jaderberg, President of Isomorphic Labs. “These translate directly into better molecular profiles with the potential to be new medicines and unlock some of the hardest problems in drug discovery. Our interdisciplinary teams combine world-leading machine learning researchers with top-class drug hunters and together they are routinely solving complex biological problems that have stalled traditional research for decades. We are translating our discoveries directly into potential life-changing medicines, built on the infrastructure we are establishing for the future of bioengineering with this investor backing.”
The new funding will help Isomorphic Labs further improve its AI drug design platform, IsoDDE. The company also plans to expand its research into new areas of biology by developing more advanced AI models.
Isomorphic Labs is also building partnerships to better understand how diseases work and develop new types of treatments. At the same time, the company is investing in global infrastructure to support the future of AI-powered drug development.
The funding will also help the company build stronger AI-based systems for drug testing and clinical development. These systems will support the progress of its potential medicines as they move towards clinical trials.